FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases
By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b of this clinical trial will study CTA313 in patients with systemic...